Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (March 2026)
14 slides from Rhythm Biosciences's investor presentation, Mar 18, 2026
Slide 1: Business Update
For personal use only Business Update 18TH MARCH 2026
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, rep
Slide 3: Agenda
Agenda o Company Summary For personal use only o Recent ASX market updates o Upcoming catalysts / inflection points? o Q&A 2 © Rhythm Biosciences 2026
Slide 4: Detecting Cancer Earlier. Saving Lives.
Detecting Cancer Earlier. Saving Lives. Our purpose is clear: through innovative diagnostics, we are enabling the earliest possible detection of cancer. For personal use only Product Strategy Growth Opportunity and Drivers EARLIEST STAGE SIGNIFICANT MULTI-$BN GLOBAL MARKET geneTypeTM Targeting the r
Slide 5: Investment Highlights
Investment Highlights CORPORATE SNAPSHOT 17th March 2026 Solving a significant and worsening global ASX Code RHY problem costing healthcare systems $billions For personal use only Share Price $0.21 Shares on Issue 329.5M Unlisted & Listed Options 109M Market Capitalisation $70.56M Portfolio of valua
Slide 6: Recent ColoSTAT ASX Market Updates
Recent ColoSTAT® ASX Market Updates 1. Rhythm ISO15189 Accreditation & ColoSTAT® Commercialisation Initiation 12 December 2025 For personal use only 2. Manufacturing Agreement for ColoSTAT® Signed 3 February 2026 3. First Physician Enrolled in the ColoSTAT® Access Program (CAP) 11 February 2026 4. C
Slide 7: ColoSTAT Achieves NATA Accreditation
ColoSTAT® Achieves NATA Accreditation 9th March 2026: The National Association of Testing Authorities (NATA) — Australia’s independent peak laboratory accreditation body — has confirmed that ColoSTAT® satisfies all applicable technical and quality requirements under ISO 15189:2022 For personal use o
Slide 8: ColoSTAT Services Agreement with 4Cyte Pathology
ColoSTAT® Services Agreement with 4Cyte Pathology 17th Feb 2026: Rhythm signs a non-exclusive ColoSTAT® distribution agreement with 4Cyte Pathology, with access to more than 1,000 pathology collection centres across NSW, VIC and QLD. For personal use only ★ WHY THIS MATTERS WHAT THIS ENABLES WHAT’S
Slide 9: First ColoSTAT Sale
First ColoSTAT® Sale 11th March 2026: Rhythm completes the first commercial sale of its blood based ColoSTAT® colorectal cancer test, marking the commencement of the Company's commercial clinical diagnostic testing operations. For personal use only ★ WHY THIS MATTERS WHAT THIS ENABLES WHAT’S NEXT •
Slide 10: RHYO Options Underwritten: $5.5m Cash Secured
RHYO Options Underwritten: $5.5m Cash Secured 25th Feb. 2026: RHY secures underwriting support for RHYO listed options expiring 31 March 2026, guaranteeing a minimum of $5.5m in new capital at $0.20 per share. For personal use only ★ WHY THIS MATTERS WHAT THIS ENABLES WHAT’S NEXT • Underwriting de-r
Slide 11: Preparing for Growth
Preparing for Growth Leveraging our core business enablers to build a resilient high growth enterprise For personal use only Product Development Optimise delivery of current portfolio Portfolio Expansion Commercial Depth Market Expansion Pilot Markets and GTM optimisation Global Expansion Global Pre
Slide 12: Upcoming Value Inflection Points
Upcoming Value Inflection Points For personal use only PRODUCT MILESTONE DESCRIPTION COMPLETION DATE ColoSTAT® Scaling commercial footprint Activation of 4Cyte collection centres Q4 FY2026 geneType strategic Establishment of key international and domestic Ongoing from Q3 geneType partnerships commer
Slide 13: Board and Management Team
Board and Management Team Highly experienced team focussed on execution For personal use only Jackson Jones Nir Dvorski Chief Commercial Officer Chief Operations Officer David Atkins, PhD Sue MacLeman Gavin Fox-Smith CEO & MD Non-Executive Director Non-Executive Chairman Former CEO of Congenica (UK)
Slide 14: Thank you!
For personal use only Thank you! david.atkins@rhythmbio.com www.rhythmbio.com
Rhythm Biosciences — Investor Presentation (March 2026) on 6ix